Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) announced that it has entered into a partnership with contract research organization KGK Science that aims to enhance health research and production innovation and establish both companies as leaders in advanced health assessment technologies.
The provider of rapid health screening solutions said that the partnership introduces a new operational vertical with "significant potential."
By incorporating its technologies into KGK Science’s clinical trials, the company believes it can redefine patient screening and health data collection accuracy, and introduce new methods of continuous monitoring.
This integration is expected to potentially significantly enhance the efficiency of clinical trials, translating into cost savings and improved return on investments for clinical research organizations.
"Our partnership with KGK Science is a testament to our shared vision for leveraging advanced health assessment technologies to open new avenues in health research and product development," Predictmedix AI chief operating officer Rahul Kushwah said in a statement.
“We are committed to this collaboration as a means to innovate and improve upon the standards of health assessments."
Predictmedix AI is an emerging provider of rapid health screening and remote patient care solutions globally. Its Safe Entry Stations - powered by a proprietary AI- use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses.